Molecular Partners and Orano Med Team Up for Alpha Radiotherapies for Cancer (MOLN: NASDAQ)


cancer patient and modern treatment

Xesai

  • Biotechnology company in clinical phase Molecular Partners (NASDAQ:CLOUD) and Orano Med, a radiopharmaceutical company in the clinical phase expand their strategic collaboration.
  • The terms of the new agreement include the development of six additional targeted alpha therapeutic candidates, now representing a total of ten potential candidates.



Source link

  • Related Posts

    Shares of ARS Pharmaceuticals rose on strong Q4 earnings for allergy spray By Investing.com

    Investing.com — ARS Pharmaceuticals stock experienced a significant uptick, surging 11%, marking its biggest intraday leap since August. This surge was prompted by the company’s announcement of preliminary fourth-quarter net…

    Truist Financial (TFC:NYSE) COO Hugh Cummins III Resigns

    J. Michael Jones/iStock Editorial via Getty Images Truist Financial (NYSE:TFC) Vice President and Chief Operating Officer Hugh S. “Beau” Cummins III will be give up your rolewith immediate effect, the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *